Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 -- 1605 2022-04-17 08:18:22 |
2 removed as it was repeated -6 word(s) 1599 2022-04-17 08:19:31 | |
3 format correct -44 word(s) 1555 2022-04-18 02:28:32 |

Video Upload Options

Do you have a full video?

Confirm

Are you sure to Delete?
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Lim, J.S.L.; Chong, P.S.Y.; Chng, W. Metabolic Vulnerabilities in Multiple Myeloma. Encyclopedia. Available online: https://encyclopedia.pub/entry/21851 (accessed on 21 June 2024).
Lim JSL, Chong PSY, Chng W. Metabolic Vulnerabilities in Multiple Myeloma. Encyclopedia. Available at: https://encyclopedia.pub/entry/21851. Accessed June 21, 2024.
Lim, Julia S. L., Phyllis Shu Yun Chong, Wee-Joo Chng. "Metabolic Vulnerabilities in Multiple Myeloma" Encyclopedia, https://encyclopedia.pub/entry/21851 (accessed June 21, 2024).
Lim, J.S.L., Chong, P.S.Y., & Chng, W. (2022, April 17). Metabolic Vulnerabilities in Multiple Myeloma. In Encyclopedia. https://encyclopedia.pub/entry/21851
Lim, Julia S. L., et al. "Metabolic Vulnerabilities in Multiple Myeloma." Encyclopedia. Web. 17 April, 2022.
Metabolic Vulnerabilities in Multiple Myeloma
Edit

Multiple myeloma (MM) remains an incurable malignancy with eventual emergence of refractory disease. Metabolic shifts, which ensure the availability of sufficient energy to support hyperproliferation of malignant cells, are a hallmark of cancer. Deregulated metabolic pathways have implications for the tumor microenvironment, immune cell function, prognostic significance in MM and anti-myeloma drug resistance.

multiple myeloma metabolism metabolic vulnerability

1. Introduction

Multiple Myeloma (MM) is a plasma cell malignancy characterized by extensive heterogenous molecular and cytogenic subtypes, resulting in varied outcomes. It is the second most prevalent hematological malignancy globally [1]. High risk translocations (4;14), (14;16), including 17p13 deletion and 1q21 amplification, are associated with adverse outcomes and the endeavor to optimally manage these groups of patients remains elusive. The advent of novel drug classes such as proteasome inhibitors (PI), immunomodulatory drugs (IMIDs) and monoclonal antibodies have improved patient survival outcomes significantly. However, a long-standing clinical challenge remains, as patients eventually develop drug resistance represented by those with relapsed or refractory MM (RRMM) [2]. Hence, it is critical for novel strategies to be identified to enhance therapeutic interventions as MM remains incurable.

Metabolic Deregulations Predict Adverse Prognosis in MM

Cancer cells adapt by reprogramming metabolic pathways, which is essential to ensuring that energy demands are met for rapid cell proliferation and tumor growth, across oxygen levels. Altered glucose and glutamine metabolism are the most well-studied pathways in MM, whereas serine metabolism and the pentose phosphate and folate pathways have also been implicated [3].
MM is a neoplasm with high prevalence in the elderly, with median age of diagnosis at 69 years [4]. The older population often present with parallel co-morbidities such as obesity, diabetes, and hyperlipidemia [5][6]. The novel association between metabolic syndrome (MS) and myeloma has recently been explored. Monoclonal proliferation of plasma cells within the bone marrow give rise to a secretion of paraproteins or M-proteins in the serum. The association of paraprotein production by myeloma cells with hyperlipidemia and low high-density lipoprotein (HDL) cholesterol has established a link between MM and features of MS [7]. Collectively, studies have found associations between MS features, inflammatory cytokines, and MM progression [8]. Moreover, some drugs indicated as treatment for metabolic disorders, including statins and metformin, could potentially improve outcomes in myeloma [9][10].

2. Physiological Role of Metabolism in Plasma Cells

Long-lived plasma cells migrate and reside in the bone marrow to secrete antibody constitutively, thereby conferring lifelong protection [11]. Their specialized function of antibody secretion and limited replicative capacity demand specialized requirements on nutrient uptake and biomolecular synthesis. Plasma cell differentiation is initiated when naïve B cells are activated, and glucose uptake increases driving glycolysis and oxidative phosphorylation [12]. Single-cell transcriptomics of long-lived vs. short-lived plasma cells showed few differences, but they mainly differed in rates of glucose and amino acid uptake, which is significantly increased in long-lived plasma cells. It is reasonable to hypothesize that the determinant of plasma cells’ lifespan is attributed to cellular metabolism and not transcriptional regulation [13].

3. Current Literature of Metabolic Abnormalities in MM

3.1 Myeloma Cells Undergo Metabolic Rewiring of Glycolysis and Mitochondria OXPHOS

Myeloma cells undergo extensive metabolic reprogramming, as is characteristic of all cancers [14]. Otto Warburg introduced the concept of the ‘Warburg effect’, referring to the hyper-elevation of glucose uptake by malignant cells. Aerobic glycolysis is a phenomenon where cancer cells metabolize glucose even in the presence of oxygen, while downregulating oxidative phosphorylation (OXPHOS). However, findings in conflict with this concept showed that many tumors had sufficient or even increased OXPHOS [15][16][17]. The dependency of MM cells on glucose has been shown to be evident by their sensitivity to multiple glycolytic inhibitors, including dichloroacetate [18]. Moreover, the expression of rate-limiting enzymes in the glycolysis pathway has been shown to be further upregulated with disease progression and to confer adverse prognosis [19]. Notably, MM cells can take up lactate exogenously through monocarboxylate transporter 1 (MCT1), thus fueling the reverse Warburg effect [20]. Notably, myeloma cells evidently metabolize using OXPHOS as a synergism between Metformin and ritonavir, an OXPHOS inhibitor and glucose uptake inhibitor, respectively, which induced apoptosis in MM cells. This suggests that the limitation of glycolysis is compensated with OXPHOS. Consistently, upon inhibition of glycolysis, glutamine dependency was demonstrated and, in this context, OXPHOS was mainly fueled by glutaminolysis [21]. Metabolic plasticity in MM cells is clearly highlighted, which presents it as a vulnerability to be targeted.

3.2 Fatty Acid Metabolism Obesity as a Risk Factor in Myeloma

The role of bone marrow adipocytes (BMA) in supporting myeloma cells is relatively under-explored despite its dynamic functions. Its multifaceted roles include endocrine secretory functions, promoting cell-to-cell communication directly, correlating with obesity, a possible role in bone disease and close proximity to myeloma cells [22][23][24][25]. BMAs may potentially supply free fatty acids to MM cells for proliferation and survival. This has implications on fatty acid metabolism including fatty acid uptake and oxidation[26]. Myeloma cells have elevated levels of fatty acid-binding proteins (FABP), which potentially enhances tumor growth[27]. Furthermore, Etomoxir, an inhibitor of fatty acid beta oxidation and orlistat, an inhibitor of de novo fatty acid synthesis, ameliorated myeloma proliferation and decreased MM survival [28].t(4;14)-positive cells showed a high dependency on the mevalonate (MVA) pathway for survival. Inhibition of the fatty acid synthesis pathway with statin specifically increased apoptosis in this subset of cells. Furthermore, statin treatment led to an activation of the integrated stress response (ISR), which was modulated by co-administration with bortezomib. Evidence from exogenous rescue using geranylgeranyl pyrophosphate (GGPP) showed that t(4;14)-positive cells require the MVA pathway for the synthesis of geranylgeranyl pyrophosphate (GGPP). Interestingly, fluvastatin treatment had synergistic effects with bortezomib in vivo[29].

Obesity is a critical component of metabolic syndrome and contributes to MM pathogenesis heterogeneously. It is often measured based on body mass index (BMI) and classified into three unique stages by the World Health Organization: stage 1 (BMI 30–34.9), stage 2 (BMI 35–39.9) and stage 3 (BMI ≥ 40) [30]. Obesity-related epidemiological findings are deeply concerning and associations to multiple cancers including MM have been reported. Wallin and Larsson meta-analyzed 19 prospective studies which consistently demonstrated statistical significance between increased MM incidence and overweight individuals [31]. Indeed, excessive body weight has been highlighted as a critical risk factor for MM progression and mortality, which is well-supported by multiple studies[32][33]. Consequently, obesity has been established as a risk factor for MM by the International Agency for Research on Cancer recently[34]. It has also been proposed that the myeloma disease burden could be reduced at the population level with obesity accounted as the sole modifiable risk factor[8].

An overview of the metabolic abnormalities in MM is schematically presented in Figure 1.
Figure 1. Schematic overview of critical metabolic alterations in myeloma and key proteins involved.

4. Clinical Implications of Metabolic Deregulation in Myeloma 

Rewired metabolism attenuates the therapeutic effects of standard-of-care drugs, largely attributed to the hypoxic tumor microenvironment in the bone marrow (BM) [36]. Hypoxia inducible factor (HIF)-1 is activated in this context, which drives glucose metabolism towards dependency on pyruvate conversion to lactate, rather than its oxidation in the mitochondria for energy production[20]. It has been postulated that drug resistance might arise through the adaptation to hypoxia in the BM, leading to relapse. Upregulation of HIF-1  and HIF-2  pathways was shown through an analysis of gene expression datasets comparing primary MM patients and healthy subjects. Importantly, a further enrichment of these pathways was evident in bortezomib-refractory and relapsed myeloma patients [37][38]. Human myeloma cell lines (HMCLs) subjected to hypoxic conditions and thereafter treated with bortezomib, dexamethasone and melphalan were observed to have increased glucose metabolism, with and overexpression of LDHA and HIF-1 post-treatment[20].

4.1 Metabolic Deregulation Attenuates Immunotherapy

Immunotherapy is presently used for treatment in MM. The array of therapeutics used in MM includes immunomodulatory drugs (IMiDs), inhibitors of immune checkpoint, vaccines derived from dendritic cells and allogenic transplantation[39]. IMiDs potentiate the proliferative and functional properties of natural killer (NK) and NK T cells. Additionally, both daratumumab, a CD38 monoclonal antibody, and immune checkpoint inhibitors have shown to enhance T cell immunity against myeloma [40]. Other immunotherapeutic strategies include the dendritic cell (DC) vaccine synthesized by DC fusion with antigen and the chimeric antigen receptor (CAR) T cell therapy which modifies autologous T cells genetically with CAR expression and the specific target of tumor antigens [41].

Despite the promising potential of immunotherapeutic strategies, they come with their own set of challenges in the context of metabolism. Alterations in metabolism in the tumor microenvironment can weaken the therapeutic effect of immunotherapy[42]. The TME confers metabolic privileges to tumor cells by increasing the rate of glucose and glutamine uptake and by excessive lactate production and secretion. This metabolic shift is unfavorable for T cell recruitment and for them to thrive, because of nutrient deprivation, extensive acidification, a build-up of waste products and hypoxia[43]. Through pH buffering with bicarbonate, the acidification of the TME could be circumvented and the efficacy of immunotherapy improved. This could potentially be applied in MM. Although 2-Deoxy-d-glucose (2DG) is used in MM to inhibit glycolysis, it is incompatible with coadministration of immunotherapeutic agents as it impairs T cell metabolism and reduces its antitumor effects[42]. Immune cells primarily metabolize amino acid, such as L-arginine, which is a non-essential amino acid found in macrophages and DCs. However, lactate secretion by tumor cells leads to an overexpression of arginase, which converts L-arginine to urea and ornithine and, consequently, an impairment of T cell function by interference with cell cycle progression. MM cells are known to secrete lactate and it can be reasonably postulated that MM cells can cause T cell dysfunction through this mechanism [44].

References

  1. Rebecca L. Siegel; Kimberly D. Miller Mph; Ahmedin Jemal; Cancer statistics, 2018. CA: A Cancer Journal for Clinicians 2018, 68, 7-30, 10.3322/caac.21442.
  2. Abdul Hamid Bazarbachi; Rama Al Hamed; Florent Malard; Jean-Luc Harousseau; Mohamad Mohty; Relapsed refractory multiple myeloma: a comprehensive overview. Leukemia 2019, 33, 2343-2357, 10.1038/s41375-019-0561-2.
  3. Chaima El Arfani; Ken Maes; Eline Menu; Kim De Veirman; Elke De Bruyne; Metabolic Features of Multiple Myeloma. International Journal of Molecular Sciences 2018, 19, 1200, 10.3390/ijms19041200.
  4. Ashley Rosko; Sergio Giralt; Maria-Victoria Mateos; Angela Dispenzieri; Myeloma in Elderly Patients: When Less Is More and More Is More. American Society of Clinical Oncology Educational Book 2017, 37, 575-585, 10.14694/edbk_175171.
  5. Craig M. Hales; Cheryl D. Fryar; Margaret D. Carroll; David S. Freedman; Cynthia L. Ogden; Trends in Obesity and Severe Obesity Prevalence in US Youth and Adults by Sex and Age, 2007-2008 to 2015-2016. JAMA 2018, 319, 1723-1725, 10.1001/jama.2018.3060.
  6. Saurabh Zanwar; Jithma Prasad Abeykoon; Prashant Kapoor; Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population. Current Hematologic Malignancy Reports 2019, 14, 70-82, 10.1007/s11899-019-00500-4.
  7. Keiichi Fukudome; Johji Kato; Tsuyosi Ohashi; Yoshitaka Yamamoto; Tanenao Eto; Hyperlipidemia Associated with Multiple Myeloma.. Internal Medicine 1996, 35, 337-340, 10.2169/internalmedicine.35.337.
  8. K R Carson; M L Bates; M H Tomasson; The skinny on obesity and plasma cell myeloma: a review of the literature. Bone Marrow Transplantation 2014, 49, 1009-1015, 10.1038/bmt.2014.71.
  9. Su-Hsin Chang; Suhong Luo; Katiuscia K O'Brian; Theodore S Thomas; Graham A Colditz; Nils P Carlsson; Kenneth R Carson; Association between metformin use and progression of monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans with diabetes mellitus: a population-based retrospective cohort study. The Lancet Haematology 2015, 2, e30-e36, 10.1016/s2352-3026(14)00037-4.
  10. Kristen Marie Sanfilippo; Jesse Keller; Brian F. Gage; Suhong Luo; Tzu-Fei Wang; Gerald Moskowitz; Jason Gumbel; Brandon Blue; Katiuscia O’Brian; Kenneth R. Carson; et al. Statins Are Associated With Reduced Mortality in Multiple Myeloma. Journal of Clinical Oncology 2016, 34, 4008-4014, 10.1200/jco.2016.68.3482.
  11. Jessica L. Halliley; Christopher M. Tipton; Jane Liesveld; Alexander F. Rosenberg; Jaime Darce; Ivan V. Gregoretti; Lana Popova; Denise Kaminiski; Christopher F. Fucile; Igor Albizua; et al.Shuya KyuKuang-Yueh ChiangKyle T. BradleyRichard BurackMark SlifkaErika HammarlundHao WuLiping ZhaoEdward E. WalshAnn R. FalseyTroy D. RandallWan Cheung CheungIñaki SanzF. Eun-Hyung Lee Long-Lived Plasma Cells Are Contained within the CD19−CD38hiCD138+ Subset in Human Bone Marrow. Immunity 2015, 43, 132-145, 10.1016/j.immuni.2015.06.016.
  12. Cheryl A. Doughty; Blair F. Bleiman; Dean J. Wagner; Fay J. Dufort; Jennifer M. Mataraza; Mary F. Roberts; Thomas C. Chiles; Antigen receptor–mediated changes in glucose metabolism in B lymphocytes: role of phosphatidylinositol 3-kinase signaling in the glycolytic control of growth. Blood 2006, 107, 4458-4465, 10.1182/blood-2005-12-4788.
  13. Wing Y. Lam; Arijita Jash; Conghui Yao; Lucas D’Souza; Rachel Wong; Ryan M. Nunley; Gordon P. Meares; Gary J. Patti; Deepta Bhattacharya; Metabolic and Transcriptional Modules Independently Diversify Plasma Cell Lifespan and Function. Cell Reports 2018, 24, 2479-2492.e6, 10.1016/j.celrep.2018.07.084.
  14. Natalya Pavlova; Craig B. Thompson; The Emerging Hallmarks of Cancer Metabolism. Cell Metabolism 2016, 23, 27-47, 10.1016/j.cmet.2015.12.006.
  15. Yuneva, M.O.; Fan, T.W.; Allen, T.D.; Higashi, R.M.; Ferraris, D.V.; Tsukamoto, T.; Matés, J.M.; Alonso, F.J.; Wang, C.; Seo, Y.; et al.et al. The Metabolic Profile of Tumors Depends on Both the Responsible Genetic Lesion and Tissue Type. . Cell Metab. 2012, 15, 157–170.
  16. Sam Weinberg; Navdeep S Chandel; Targeting mitochondria metabolism for cancer therapy. Nature Chemical Biology 2014, 11, 9-15, 10.1038/nchembio.1712.
  17. Christopher T. Hensley; Brandon Faubert; Qing Yuan; Naama Lev-Cohain; Eunsook Jin; Jiyeon Kim; Lei Jiang; Bookyung Ko; Rachael Skelton; Laurin Loudat; et al.Michelle WodzakClaire KlimkoElizabeth McMillanYasmeen ButtMin NiDwight OliverJose TorrealbaCraig MalloyKemp KernstineRobert LenkinskiRalph J. DeBerardinis Metabolic Heterogeneity in Human Lung Tumors. Cell 2016, 164, 681-694, 10.1016/j.cell.2015.12.034.
  18. W. Y. Sanchez; Sean McGee; T. Connor; B. Mottram; Andrew Wilkinson; Jonathan Whitehead; S. Vuckovic; L. Catley; Dichloroacetate inhibits aerobic glycolysis in multiple myeloma cells and increases sensitivity to bortezomib. British Journal of Cancer 2013, 108, 1624-1633, 10.1038/bjc.2013.120.
  19. Patricia Maiso; Daisy Huynh; Michele Moschetta; Antonio Sacco; Yosra Aljawai; Yuji Mishima; John M. Asara; Aldo M. Roccaro; Alec C. Kimmelman; Irene M. Ghobrial; et al. Metabolic Signature Identifies Novel Targets for Drug Resistance in Multiple Myeloma. Cancer Research 2015, 75, 2071-2082, 10.1158/0008-5472.can-14-3400.
  20. Shiho Fujiwara; Naoko Wada; Yawara Kawano; Yutaka Okuno; Yoshitaka Kikukawa; Shinya Endo; Nao Nishimura; Nina Ueno; Hiroaki Mitsuya; Hiroyuki Hata; et al. Lactate, a putative survival factor for myeloma cells, is incorporated by myeloma cells through monocarboxylate transporters 1. Experimental Hematology & Oncology 2015, 4, 1-8, 10.1186/s40164-015-0008-z.
  21. Sevim Dalva-Aydemir; Richa Bajpai; Maylyn Martinez; Kehinde U.A. Adekola; Irawati Kandela; Changyong Wei; Seema Singhal; Jennifer Koblinski; Noopur S. Raje; Steven T. Rosen; et al.Mala Shanmugam Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin. Clinical Cancer Research 2014, 21, 1161-1171, 10.1158/1078-0432.ccr-14-1088.
  22. Michelle M. McDonald; Heather Fairfield; Carolyne Falank; Michaela R. Reagan; Adipose, Bone, and Myeloma: Contributions from the Microenvironment. Calcified Tissue International 2016, 100, 433-448, 10.1007/s00223-016-0162-2.
  23. Carolyne Falank; Heather Fairfield; Michaela R. Reagan; Signaling Interplay between Bone Marrow Adipose Tissue and Multiple Myeloma cells. Frontiers in Endocrinology 2016, 7, 67, 10.3389/fendo.2016.00067.
  24. Jessica A. Fowler; Seint T. Lwin; Matthew T. Drake; James R. Edwards; Robert A. Kyle; Gregory R. Mundy; Claire Edwards; Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood 2011, 118, 5872-5882, 10.1182/blood-2011-01-330407.
  25. William P. Cawthorn; Erica Scheller; Brian S. Learman; Sebastian D. Parlee; Becky R. Simon; Hiroyuki Mori; Xiaomin Ning; Adam J. Bree; Benjamin Schell; David T. Broome; et al.Sandra S. SolimanJenifer L. DelPropostoCarey N. LumengAditi MitraSandeep V. PanditKatherine A. GallagherJoshua D. MillerVenkatesh KrishnanSusanta K. HuiMiriam A. BredellaPouneh K. FazeliAnne KlibanskiMark C. HorowitzClifford J. RosenOrmond A. MacDougald Bone Marrow Adipose Tissue Is an Endocrine Organ that Contributes to Increased Circulating Adiponectin during Caloric Restriction. Cell Metabolism 2014, 20, 368-375, 10.1016/j.cmet.2014.06.003.
  26. Majdi Masarwi; Abigail DeSchiffart; Justin Ham; Michaela R. Reagan; Multiple Myeloma and Fatty Acid Metabolism. JBMR Plus 2019, 3, e10173, 10.1002/jbm4.10173.
  27. Petra Schneiderova; Tomas Pika; Petr Gajdos; Regina Fillerova; Pavel Kromer; Milos Kudelka; Jiri Minarik; Tomas Papajik; Vlastimil Scudla; Eva Kriegova; et al. Serum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myeloma. Oncotarget 2016, 8, 69408-69421, 10.18632/oncotarget.11242.
  28. Jm Tirado-Velez; Insaf Joumady; Ana Saez-Benito; Irene Cozar-Castellano; Germán Perdomo; Inhibition of Fatty Acid Metabolism Reduces Human Myeloma Cells Proliferation. PLoS ONE 2012, 7, e46484, 10.1371/journal.pone.0046484.
  29. Joseph Longo; Petr Smirnov; Zhihua Li; Emily Branchard; Jenna E. van Leeuwen; Jonathan D. Licht; Benjamin Haibe-Kains; David W. Andrews; Jonathan J. Keats; Trevor J. Pugh; et al.Suzanne TrudelLinda Z. Penn The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma. Leukemia 2020, 35, 796-808, 10.1038/s41375-020-0962-2.
  30. Sophie C. Ragbourne; Negar Maghsoodi; Matthew Streetly; Martin A. Crook; The Association between Metabolic Syndrome and Multiple Myeloma. Acta Haematologica 2020, 144, 24-33, 10.1159/000505992.
  31. Alice Wallin; Susanna C. Larsson; Body mass index and risk of multiple myeloma: A meta-analysis of prospective studies. European Journal of Cancer 2011, 47, 1606-1615, 10.1016/j.ejca.2011.01.020.
  32. Jonathan N. Hofmann; Steven C. Moore; Unhee Lim; Yikyung Park; Dalsu Baris; Albert R. Hollenbeck; Charles E. Matthews; Todd M. Gibson; Patricia Hartge; Mark P. Purdue; et al. Body Mass Index and Physical Activity at Different Ages and Risk of Multiple Myeloma in the NIH-AARP Diet and Health Study. American Journal of Epidemiology 2013, 177, 776-786, 10.1093/aje/kws295.
  33. Lauren R. Teras; Cari M. Kitahara; Brenda Birmann; Patricia A. Hartge; Sophia S. Wang; Kim Robien; Alpa V. Patel; Hans-Olov Adami; Elisabete Weiderpass; Graham Giles; et al.Pramil SinghMichael AlavanjaLaura E. Beane FreemanLeslie BernsteinJulie E. BuringGraham ColditzGary E. FraserSusan M. GapsturJ. Michael GazianoEdward GiovannucciJonathan HofmannMartha S. LinetGila NetaYikyung ParkUlrike PetersPhilip RosenbergCatherine SchairerHoward D. SessoMeir J. StampferKala VisvanathanEmily WhiteAlicja WolkAnne Zeleniuch-JacquotteAmy Berrington De GonzálezMark Purdue Body size and multiple myeloma mortality: a pooled analysis of 20 prospective studies. British Journal of Haematology 2014, 166, 667-676, 10.1111/bjh.12935.
  34. Beatrice Lauby-Secretan; Chiara Scoccianti; Dana Loomis; Yann Grosse; Franca Bianchini; Kurt Straif; Body Fatness and Cancer — Viewpoint of the IARC Working Group. New England Journal of Medicine 2016, 375, 794-798, 10.1056/nejmsr1606602.
  35. Cancer Metabolism in Nutrient Replete Conditions, by BioRender.com. 2022. Available online: https://app.biorender.com/ biorender-templates (accessed on 15 February 2022)
  36. Nicholas C. Denko; Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nature Reviews Cancer 2008, 8, 705-713, 10.1038/nrc2468.
  37. Cheryl A. Doughty; Blair F. Bleiman; Dean J. Wagner; Fay J. Dufort; Jennifer M. Mataraza; Mary F. Roberts; Thomas C. Chiles; Antigen receptor–mediated changes in glucose metabolism in B lymphocytes: role of phosphatidylinositol 3-kinase signaling in the glycolytic control of growth. Blood 2006, 107, 4458-4465, 10.1182/blood-2005-12-4788.
  38. George Mulligan; Constantine Mitsiades; Barbara Bryant; Fenghuang Zhan; Wee J. Chng; Steven Roels; Erik Koenig; Andrew Fergus; Yongsheng Huang; Paul Richardson; et al.William L. TrepicchioAnnemiek BroylPieter SonneveldJohn D. ShaughnessyP. Leif BergsagelDavid SchenkeinDixie-Lee EsseltineAnthony BoralKenneth C. Anderson Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2006, 109, 3177-3188, 10.1182/blood-2006-09-044974.
  39. Hideto Tamura; Immunopathogenesis and immunotherapy of multiple myeloma. International Journal of Hematology 2018, 107, 278-285, 10.1007/s12185-018-2405-7.
  40. Jakub Krejcik; Kristine A Frerichs; Inger S. Nijhof; Berris Van Kessel; Jeroen F. Van Velzen; Andries C. Bloem; Marloes E.C. Broekmans; Sonja Zweegman; Johan Van Meerloo; René J.P. Musters; et al.Pino J. PoddigheRichard GroenChristopher ChiuTorben PlesnerHenk M. LokhorstA. Kate SasserTuna MutisNiels W.C.J. Van De Donk Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab. Clinical Cancer Research 2017, 23, 7498-7511, 10.1158/1078-0432.ccr-17-2027.
  41. Hosen, N.; Matsunaga, Y.; Hasegawa, K.; Matsuno, H.; Nakamura, Y.; Makita, M.; Watanabe, K.; Yoshida, M.; Satoh, K.; Morimoto, S.; et al.et al. The activated conformation of integrin 7 is a novel multiple myeloma–specific target for CAR T cell therapy. . Nat. Med. 2017, 23, 1436–1443.
  42. Soumaya Kouidhi; Farhat Ben Ayed; Amel Benammar Elgaaied; Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy. Frontiers in Immunology 2018, 9, 353, 10.3389/fimmu.2018.00353.
  43. Kathryn E. Beckermann; Stephanie O. Dudzinski; Jeffrey C. Rathmell; Dysfunctional T cell metabolism in the tumor microenvironment. Cytokine & Growth Factor Reviews 2017, 35, 7-14, 10.1016/j.cytogfr.2017.04.003.
  44. Grégory Noël; Mireille Langouo Fontsa; Karen Willard-Gallo; The impact of tumor cell metabolism on T cell-mediated immune responses and immuno-metabolic biomarkers in cancer. Seminars in Cancer Biology 2018, 52, 66-74, 10.1016/j.semcancer.2018.03.003.
More
Information
Subjects: Hematology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : , ,
View Times: 355
Revisions: 3 times (View History)
Update Date: 18 Apr 2022
1000/1000
Video Production Service